Clindamycin

Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs) . Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA) . Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla) . Clindamycin also can be used for researching malaria[1][2].

Product Specifications

CAS Number

[18323-44-9]

UNSPSC

12352005

Hazard Statement

H301-H311-H331-H341

Target

Antibiotic; Bacterial; Parasite

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/clindamycin.html

Purity

99.90

Solubility

DMSO : 125 mg/mL (ultrasonic) |H2O : 2 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CN(C[C@H](CCC)C1)[C@@H]1C(N[C@@]([C@@H](Cl)C)([H])[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)=O

Molecular Formula

C18H33ClN2O5S

Molecular Weight

424.98

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P361-P403+P233-P405-P501

References & Citations

[7]Yang SH, Lee MG. Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability. Int J Pharm. 2007 Mar 6;332 (1-2) :17-23.|[8]Hirata N, et al. Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob Agents Chemother. 2001 Sep;45 (9) :2638-42. |[1]Hodille E, et al. Clindamycin suppresses virulence expression in inducible clindamycin-resistant Staphylococcus aureus strains. Ann Clin Microbiol Antimicrob. 2018 Oct 20;17 (1) :38.|[2]Kremsner PG. Clindamycin in malaria treatment. J Antimicrob Chemother. 1990 Jan;25 (1) :9-14.|[3]Kishi K, et al. Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55:B5 and subsequent production of tumor necrosis factor alpha and interleukin-1 beta. Antimicrob Agents Chemother. 1999 Mar;43 (3) :616-22.|[4]Veringa EM, et al. Clindamycin at subinhibitory concentrations enhances antibody- and complement-dependent phagocytosis by human polymorphonuclear leukocytes of Staphylococcus aureus. Chemotherapy. 1987;33 (4) :243-9. |[5]Naal FD, et al. The effects of clindamycin on human osteoblasts in vitro. Arch Orthop Trauma Surg. 2008 Mar;128 (3) :317-23.|[6]Faggion PI, et al. Is the penetration of clindamycin into the masseter muscle really enough to treat odontogenic infections? Clin Oral Investig. 2021 May;25 (5) :3257-3266.